Page 1
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENGERIX-B safely and effectively. See full prescribing information for ENGERIX-B. ENGERIX-B [Hepatitis B Vaccine (Recombinant)] injectable suspension, for intramuscular use Initial U.S. Approval: 1989 ----------------------------- INDICATIONS AND USAGE---------------------------- ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus. (1) ------------------------- DOSAGE AND ADMINISTRATION ----------------------- For intramuscular use. (2.2) • Persons from birth through 19 years of age: A series of 3 doses (0.5 mL each) on a 0-, 1-, 6-month schedule. (2.3) • Persons 20 years of age and older: A series of 3 doses (1 mL each) on a 0-, 1-, 6-month schedule. (2.3) • Adults on hemodialysis: A series of 4 doses (2 mL each) as a single 2 mL dose or as two 1 mL doses on a 0-, 1-, 2-, 6-month schedule. (2.3) --------------------- DOSAGE FORMS AND STRENGTHS---------------------- Injectable suspension available in the following presentations: • 0.5 mL (10 mcg) prefilled syringes (3) • 1 mL (20 mcg) single dose vials and prefilled syringes (3) -------------------------------- CONTRAINDICATIONS ------------------------------ Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B-containing vaccine, or to any component of ENGERIX-B, including yeast. (4) ------------------------ WARNINGS AND PRECAUTIONS ----------------------- • Syncope (fainting) can occur in association with administration of injectable vaccines, including ENGERIX-B. Procedures should be in place to avoid injury from fainting. (5.1) • Temporarily defer vaccination of infants with a birth weight less than 2,000 g born to hepatitis B surface antigen (HBsAg)-negative mothers. (5.2) • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including ENGERIX-B, to infants born prematurely should be based on consideration of the infant’s medical status, and the potential benefits and possible risks of vaccination. (5.3) ------------------------------- ADVERSE REACTIONS ------------------------------ The most common solicited adverse reactions were injection-site soreness (22%) and fatigue (14%). (6.1) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov. ------------------------ USE IN SPECIFIC POPULATIONS ----------------------- Antibody responses are lower in persons older than 60 years than in younger adults. (8.5) See 17 for PATIENT COUNSELING INFORMATION. Revised: 5/2026 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Preparation for Administration 2.2 Administration 2.3 Recommended Dose and Schedule 2.4 Alternate Dosing Schedules 2.5 Booster Vaccinations 2.6 Known or Presumed Exposure to Hepatitis B Virus 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Syncope 5.2 Infants Weighing Less than 2,000 g at Birth 5.3 Apnea in Premature Infants 5.4 Preventing and Managing Allergic Reactions 5.5 Moderate or Severe Acute Illness 5.6 Altered Immunocompetence 5.7 Multiple Sclerosis 5.8 Limitations of Vaccine Effectiveness 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Interference with Laboratory Tests 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Efficacy in Neonates 14.2 Efficacy and Immunogenicity in Specific Populations 14.3 Immunogenicity in Neonates 14.4 Immunogenicity in Children and Adults 14.5 Interchangeability with Other Hepatitis B Vaccines 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. 2 DOSAGE AND ADMINISTRATION For intramuscular use. See Section 2.2 for subcutaneous use in persons at risk of hemorrhage.
